Metabolomics in toxicology: Preclinical and clinical applications

Toxicological Sciences

Volumn 120, Issue SUPPL.1, 2011, Pages

  Robertson, Donald G ^a   Watkins, Paul B ^b,c   Reily, Michael D ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Hamner University of North Carolina   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Mechanisms of toxicity; Metabolic profiling; Metabolomics; Metabonomics

Indexed keywords

3 METHYLHISTIDINE; ACETYLFELININE; ACYLCARNITINE; ASCORBIC ACID; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; CERIVASTATIN; GALACTOSAMINE; HISTIDINE; HYDROXYBUTYRIC ACID; INDOLELACTIC ACID; PARACETAMOL; PHYTOCHELATIN SYNTHASE; PROPIONYL CARNITINE; PYROGLUTAMIC ACID; SARCOSINE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BILE; BILE DUCT CANCER; BLOOD; BREAST CANCER; BREATHING; CANCER CELL CULTURE; CARCINOGENESIS; CIRCADIAN RHYTHM; COLON CANCER; DIABETES MELLITUS; DIET; DISEASE PREDISPOSITION; DRUG INDUSTRY; ELECTROSPRAY; ENTERITIS; ENVIRONMENTAL EXPOSURE; EPIGENETICS; FATTY LIVER; FECES; GOVERNMENT; HEALTH CARE ORGANIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUNTINGTON CHOREA; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MASS FRAGMENTOGRAPHY; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; METABOLIC SYNDROME X; METABOLOME; METABOLOMICS; MOUTH CANCER; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OVARY CANCER; PANCREAS CANCER; PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; PROSTATE FLUID; PUBLICATION; REPERFUSION INJURY; REVIEW; SALIVA; SCIENTIST; SEX DIFFERENCE; SPINOCEREBELLAR DEGENERATION; STRAIN DIFFERENCE; SYSTEMS BIOLOGY; TECHNOLOGY; TOXICOLOGY; URINE; WEIGHT REDUCTION;

ANIMALS; BIBLIOMETRICS; BIOLOGICAL MARKERS; DRUG EVALUATION, PRECLINICAL; HUMANS; METABOLIC DETOXICATION, DRUG; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS; TOXICOLOGY; XENOBIOTICS;

EID: 79952079197     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq358     Document Type: Review

References (293)

1. Ala-Korpela, M. (2008). Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin. Chem. Lab. Med. 46, 27-42.
2. Altmaier, E., Ramsay, S. L., Graber, A., Mewes, H. W., Weinberger, K. M., and Suhre, K. (2008). Bioinformatics analysis of targeted metabolomics-uncovering old and new tales of diabetic mice under medication. Endocrinology 149, 3478-3489.
3. Amacher, D. E. (2010). The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicol. Mech. Methods 20, 159-166.
4. An, J., Muoio, D. M., Shiota, M., Fujimoto, Y., Cline, G. W., Shulman, G. I., Koves, T. R., Stevens, R., Millington, D., and Newgard, C. B. (2004). Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 10, 268-274.
5. Andersson, U., Lindberg, J., Wang, S., Balasubramanian, R., Marcusson-Stahl, M., Hannula, M., Zeng, C., Juhasz, P. J., Kolmert, J., Backstrom, J., et al. (2009). A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 14, 572-586.
6. Anonymous. (2010a). NIST Home Page. Available at: http://www.nist.gov/index.html. Accessed November 12, 2010.
7. Anonymous. (2010b). Scopus Home Page, p. Scopus Home page. Available at: http://www.scopus.com/home.url. Accessed November 12, 2010.
8. Antoine, D. J., Mercer, A. E., Williams, D. P., and Park, B. K. (2009). Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica 39, 565-577.
9. Aranibar, N., Bhaskaran, V., Ott, K. H., Vassallo, J., Nelson, D., Lecureux, L., Gong, L., Stryker, S., and Lehman-McKeeman, L. (2009). Modulation of ascorbic acid metabolism by cytochrome P450 induction revealed by metab-onomics and transcriptional profiling. Magn. Reson. Chem. 47(Suppl. 1), S12-S99.
10. Aranibar, N., Vassallo, J. D., Rathmacher, J., Stryker, S., Zhang, Y., Dai, J., Janovitz, E. B., Robertson, D., Reily, M., and Lehman-McKeeman, L. (2010). Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by NMR-based metabolic profiling. Anal. Biochem. Accessed November 23, 2010. doi: 10.1016/j.ab.2010.11.023.
11. Assfalg, M., Bertini, I., Colangiuli, D., Luchinat, C., Schafer, H., Schutz, B., and Spraul, M. (2008). Evidence of different metabolic phenotypes in humans. Proc. Natl. Acad. Sci. U.S.A. 105, 1420-1424.
12. Assou, S., Haouzi, D., De Vos, J., and Hamamah, S. (2010). Human cumulus cells as biomarkers for embryo and pregnancy outcomes. Mol. Hum. Reprod. 16, 531-538.
13. Atherton, H. J., Bailey, N. J., Zhang, W., Taylor, J., Major, H., Shockcor, J., Clarke, K., and Griffin, J. L. (2006). A combined 1H NMR spectroscopy and mass spectrometry-based metabolomic study of the PPAR-{alpha} null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol. Genomics 5, 259.
14. Atzori, L., Antonucci, R., Barberini, L., Griffin, J. L., and Fanos, V. (2009). Metabolomics: a new tool for the neonatologist. J. Matern. Fetal Neonatal Med. 22(Suppl. 3), 50-53.
15. Backshall, A., Alferez, D., Teichert, F., Wilson, I. D., Wilkinson, R. W., Goodlad, R. A., and Keun, H. C. (2009). Detection of metabolic alterations in non-tumor gastrointestinal tissue of the Apc(Min/+) mouse by (1)H MAS NMR spectroscopy. J. Proteome Res. 8, 1423-1430.
16. Bailey, W. J., and Ulrich, R. (2004). Molecular profiling approaches for identifying novel biomarkers. Expert Opin. Drug Saf. 3, 137-151.
17. Bartella, L., and Huang, W. (2007). Proton (1H) MR spectroscopy of the breast. Radiographics 27(Suppl. 1), S241-S252.
18. Bartella, L., Thakur, S. B., Morris, E. A., Dershaw, D. D., Huang, W., Chough, E., Cruz, M. C., and Liberman, L. (2007). Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 245, 80-87.
19. Basanta, M., Jarvis, R. M., Xu, Y., Blackburn, G., Tal-Singer, R., Woodcock, A., Singh, D., Goodacre, R., Thomas, C. L., and Fowler, S. J. (2010). Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst. 135, 315-320.
20. Bathen, T. F., Jensen, L. R., Sitter, B., Fjosne, H. E., Halgunset, J., Axelson, D. E., Gribbestad, I. S., and Lundgren, S. (2007). MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res. Treat. 104, 181-189.
21. Beckmann, M., Parker, D., Enot, D. P., Duval, E., and Draper, J. (2008). High-throughput, nontargeted metabolite fingerprinting using nominal mass flow injection electrospray mass spectrometry. Nat. Protoc. 3, 486-504.
22. Beger, R. D., Sun, J., and Schnackenberg, L. K. (2010). Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243, 154-166.
23. Bernini, P., Bertini, I., Luchinat, C., Nepi, S., Saccenti, E., Schafer, H., Schutz, B., Spraul, M., and Tenori, L. (2009). Individual human phenotypes in metabolic space and time. J. Proteome Res. 8, 4264-4271.
24. Bezabeh, T., Somorjai, R. L., and Smith, I. C. (2009). MR metabolomics of fecal extracts: applications in the study of bowel diseases. Magn. Reson. Chem. 47(Suppl. 1), S54-S61.
25. Boernsen, K. O., Gatzek, S., and Imbert, G. (2005). Controlled protein precipitation, in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. Anal. Chem. 77, 7255-7264.
26. Bollard, M. E., Holmes, E., Lindon, J. C., Mitchell, S. C., Branstetter, D., Zhang, W., and Nicholson, J. K. (2001). Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution (1)H NMR spectroscopy of urine and pattern recognition. Anal. Biochem. 295, 194-202.
27. Bollard, M. E., Stanley, E. G., Lindon, J. C., Nicholson, J. K., and Holmes, E. (2005). NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 18, 143-162.
28. Botros, L., Sakkas, D., and Seli, E. (2008). Metabolomics and its application for non-invasive embryo assessment in IVF. Mol. Hum. Reprod. 14, 679-690.
29. Boudonck, K. J., Mitchell, M. W., Nemet, L., Keresztes, L., Nyska, A., Shinar, D., and Rosenstock, M. (2009). Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 37, 280-292.
30. Bromer, J. G., and Seli, E. (2008). Assessment of embryo viability in assisted reproductive technology: shortcomings of current approaches and the emerging role of metabolomics. Curr. Opin. Obstet. Gynecol. 20, 234-241.
31. Brown, S. C., Kruppa, G., and Dasseux, J. L. (2005). Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom. Rev. 24, 223-231.
32. Cai, S., Huo, T., Li, N., Xiong, Z., and Li, F. (2009). Lysophosphatidylcholine-biomarker of metformin action: studied using UPLC/MS/MS. Biomed. Chromatogr. 23, 782-786.
33. Calvani, R., Miccheli, A., Capuani, G., Tomassini Miccheli, A., Puccetti, C., Delfini, M., Iaconelli, A., Nanni, G., and Mingrone, G. (2010). Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int. J. Obes. 34, 1095-1098.
34. Carrasco-Pancorbo, A., Nevedomskaya, E., Arthen-Engeland, T., Zey, T., Zurek, G., Baessmann, C., Deelder, A. M., and Mayboroda, O. A. (2009). Gas chromatography/atmospheric pressure chemical ionization-time of flight mass spectrometry: analytical validation and applicability to metabolic profiling. Anal. Chem. 81, 10071-10079.
35. Cheng, L. L., Wu, C., Smith, M. R., and Gonzalez, R. G. (2001). Nondestructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett. 494, 112-116.
36. Cho, J. Y., Kang, D. W., Ma, X., Ahn, S. H., Krausz, K. W., Luecke, H., Idle, J. R., and Gonzalez, F. J. (2009). Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J. Lipid Res. 50, 924-937.
37. Cho, J. Y., Matsubara, T., Kang, D. W., Ahn, S. H., Krausz, K. W., Idle, J. R., Luecke, H., and Gonzalez, F. J. (2010). Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J. Lipid Res. 51, 1063-1074.
38. Chung, Y. L., and Griffiths, J. R. (2007). Using metabolomics to monitor anticancer drugs. Ernst Schering Found. Symp. Proc. 4, 55-78.
39. Clarke, C. J., and Haselden, J. N. (2008). Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol. 36, 140-147.
40. Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., and Di Leo, A. (2007). Metabolomics: available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 25, 2840-2846.
41. Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., and Nicholson, J. K. (2009). Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U.S.A. 106, 14728-14733.
42. Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J. P., Le Net, J. L., Baker, D., Walley, R. J., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077.
43. Coen, M., Hong, Y. S., Clayton, T. A., Rohde, C. M., Pearce, J. T., Reily, M. D., Robertson, D. G., Holmes, E., Lindon, J. C., and Nicholson, J. K. (2007). The mechanism of galactosamine toxicity revisited; a metabonomic study. J. Proteome Res. 6, 2711-2719.
44. Coen, M., Want, E. J., Clayton, T. A., Rhode, C. M., Hong, Y. S., Keun, H. C., Cantor, G. H., Metz, A. L., Robertson, D. G., Reily, M. D., et al. (2009). Mechanistic aspects and novel biomarkers of responder and non-responder phenotypes in galactosamine-induced hepatitis. J. Proteome Res. 8, 5175-5187.
45. Colatsky, T. J., and Sumner, S. (2003). Metabolic profiling and biomarker discovery. Curr. Opin. Invest. Drugs 4, 262-263.
46. Connor, S. C., Hansen, M. K., Corner, A., Smith, R. F., and Ryan, T. E. (2010). Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol. Biosyst. 6, 909-921.
47. Cox, J., Williams, S., Grove, K., Lane, R. H., and Aagaard-Tillery, K. M. (2009). A maternal high-fat diet is accompanied by alterations in the fetal primate metabolome. Am. J. Obstet. Gynecol. 201, 281.e1-281.e9.
48. Cui, Q., Lewis, I. A., Hegeman, A. D., Anderson, M. E., Li, J., Schulte, C. F., Westler, W. M., Eghbalnia, H. R., Sussman, M. R., and Markley, J. L. (2008). Metabolite identification via the Madison Metabolomics Consortium Database [3]. Nat. Biotechnol. 26, 162-164.
49. Cuperlovic-Culf, M., Barnett, D. A., Culf, A. S., and Chute, I. (2010). Cell culture metabolomics: applications and future directions. Drug Discov. Today Accessed June 30, 2010. doi:10.1016/j.drudis.2010.06.012.
50. Daykin, C. A., and Wulfert, F. (2006). NMR spectroscopy based metabo-nomics: current technology and applications. Frontiers in Drug Design and Discovery 2, 151-173.
51. Deepinder, F., Chowdary, H. T., and Agarwal, A. (2007). Role of metabolomic analysis of biomarkers in the management of male infertility. Expert Rev. Mol. Diagn. 7, 351-358.
52. DeSilva, M. A., Shanaiah, N., Gowda, G. A. N., Rosa-Perez, K., Hanson, B. A., and Raftery, D. (2009). Application of 31P NMR spectroscopy and chemical derivatization for metabolite profiling of lipophilic compounds in human serum. Magn. Reson. Chem. 47, S74-S80.
53. Dieterle, F., Schlotterbeck, G., Binder, M., Ross, A., Suter, L., and Senn, H. (2007). Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates. Chem. Res. Toxicol. 20, 1291-1299.
54. Dieterle, F., Schlotterbeck, G., Ross, A., Niederhauser, U., and Senn, H. (2006). Application of metabonomics in a compound ranking study in early drug development revealing drug-induced excretion of choline into urine. Chem. Res. Toxicol. 19, 1175-1181.
55. Dieterle, F., Sistare, F., Goodsaid, F., Papaluca, M., Ozer, J. S., Webb, C. P., Baer, W., Senagore, A., Schipper, M. J., Vonderscher, J., et al. (2010). Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 28, 455-462.
56. Dowling, C., Bollen, A. W., Noworolski, S. M., McDermott, M. W., Barbaro, N. M., Day, M. R., Henry, R. G., Chang, S. M., Dillon, W. P., Nelson, S. J., et al. (2001). Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am. J. Neuroradiol. 22, 604-612.
57. Duarte, I. F., Marques, J., Ladeirinha, A. F., Rocha, C., Lamego, I., Calheiros, R., Silva, T. M., Marques, M. P., Melo, J. B., Carreira, I. M., et al. (2009). Analytical approaches toward successful human cell metabolome studies by NMR spectroscopy. Anal. Chem. 81, 5023-5032.
58. Dumas, M. E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006). Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. U.S.A. 103, 12511-12516.
59. Dunckley, T., Coon, K. D., and Stephan, D. A. (2005). Discovery and development of biomarkers of neurological disease. Drug Discov. Today 10, 326-334.
60. Dunn, W. B. (2008). Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes. Phys. Biol. 5.
61. Ebbels, T. M., Keun, H. C., Beckonert, O. P., Bollard, M. E., Lindon, J. C., Holmes, E., and Nicholson, J. K. (2007). Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 6, 4407-4422.
62. Evelhoch, J., Garwood, M., Vigneron, D., Knopp, M., Sullivan, D., Menkens, A., Clarke, L., and Liu, G. (2005). Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res. 65, 7041-7044.
63. Fan, T. W. M., Lane, A. N., Higashi, R. M., Farag, M. A., Gao, H., Bousamra, M., and Miller, D. M. (2009). Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 8.
64. Fava, F., Lovegrove, J. A., Gitau, R., Jackson, K. G., and Tuohy, K. M. (2006). The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. Curr. Med. Chem. 13, 3005-3021.
65. Fiehn, O. (2001). Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp. Funct. Genomics 2, 155-168.
66. Fiehn, O. (2002). Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155-171.
67. Fiehn, O. (2008). Extending the breadth of metabolite profiling by gas chromatography coupled to mass spectrometry. Trends Analyt. Chem. 27, 261-269.
68. Fiehn, O., Kloska, S., and Altmann, T. (2001). Integrated studies on plant biology using multiparallel techniques. Curr. Opin. Biotechnol. 12, 82-86.
69. Gall, W. E., Beebe, K., Lawton, K. A., Adam, K. P., Mitchell, M. W., Nakhle, P. J., Ryals, J. A., Milburn, M. V., Nannipieri, M., Camastra, S., et al. (2010). Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 5, e10883.
70. Gao, H., Dong, B., Liu, X., Xuan, H., Huang, Y., and Lin, D. (2008). Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta 624, 269-277.
71. Gao, H., Lu, Q., Liu, X., Cong, H., Zhao, L., Wang, H., and Lin, D. (2009). Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 100, 782-785.
72. Garcia-Perez, I., Vallejo, M., Garcia, A., Legido-Quigley, C., and Barbas, C. (2008). Metabolic fingerprinting with capillary electrophoresis. J. Chromatogr. A 1204, 130-139.
73. Gavaghan, C. L., Holmes, E., Lenz, E., Wilson, I. D., and Nicholson, J. K. (2000). An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett. 484, 169-174.
74. Giavalisco, P., Hummel, J., Lisec, J., Inostroza, A. C., Catchpole, G., and Willmitzer, L. (2008). High-resolution direct infusion-based mass spectrom-etry in combination with whole13C metabolome isotope labeling allows unambiguous assignment of chemical sum formulas. Anal. Chem. 80, 9417-9425.
75. Glunde, K., and Serkova, N. J. (2006). Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7, 1109-1123.
76. Go, E. P. (2010). Database resources in metabolomics: an overview. J. Neuroimmune Pharmacol. 5, 18-30.
77. Goldsmith, P., Fenton, H., Morris-Stiff, G., Ahmad, N., Fisher, J., and Prasad, K. R. (2010). Metabonomics: a useful tool for the future surgeon. J. Surg. Res. 160, 122-132.
78. Gomase, V. S., Changbhale, S. S., Patil, S. A., and Kale, K. V. (2008). Metabolomics. Curr. Drug Metab. 9, 89-98.
79. Gonzalez-Angulo, A. M., Hennessy, B. T., and Mills, G. B. (2010). Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783.
80. Goodacre, R., Vaidyanathan, S., Dunn, W. B., Harrigan, G. G., and Kell, D. B. (2004). Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 22, 245-252.
81. Goonewardena, S. N., Prevette, L. E., and Desai, A. A. (2010). Metabolomics and atherosclerosis. Curr. Atheroscler. Rep. 12, 267-272.
82. Gottschalk, M., Ivanova, G., Collins, D. M., Eustace, A., O'Connor, R., and Brougham, D. F. (2008). Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts. NMR Biomed. 21, 809-819.
83. Gowda, G. A., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., and Raftery, D. (2008). Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 8, 617-633.
84. Gowda, G. A. N., Ijiare, O. B., and Shanaiah, N. (2009). Combining nuclear magnetic resonance spectroscopy and mass spectrometry in biomarker discovery. Biomarkers Med. 3, 307-322.
85. Graca, G., Duarte, I. F., Barros, A. S., Goodfellow, B. J., Diaz, S., Carreira, I. M., Couceiro, A. B., Galhano, E., and Gil, A. M. (2009). (1)H NMR based metabonomics of human amniotic fluid for the metabolic characterization of fetus malformations. J. Proteome Res. 8, 4144-4150.
86. Griffin, J. L. (2004). Metabolic profiles to define the genome: can we hear the phenotypes? Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 857-871.
87. Griffin, J. L. (2006). Understanding mouse models of disease through metabolomics. Curr. Opin. Chem. Biol. 10, 309-315.
88. Griffin, J. L., Cemal, C. K., and Pook, M. A. (2004). Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol. Genomics 16, 334-340.
89. Gu, H., Pan, Z., Xi, B., Hainline, B. E., Shanaiah, N., Asiago, V., Gowda, G. A., and Raftery, D. (2009). 1H NMR metabolomics study of age profiling in children. NMR Biomed. 22, 826-833.
90. Guan, W., Zhou, M., Hampton, C. Y., Benigno, B. B., Walker, L. D., Gray, A., McDonald, J. F., and Fernandez, F. M. (2009). Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics 10, 259.
91. Hansen, M. A. E., and Smedsgaard, J. (2007). Automated work-flow for processing high-resolution direct infusion electrospray ionization mass spectral fingerprints. Metabolomics 3, 41-54.
92. Harrigan, G. G., and Yates, L. A. (2006). High-throughput screening, metabolomics and drug discovery. IDrugs 9, 188-192.
93. Hodson, M. P., Dear, G. J., Roberts, A. D., Haylock, C. L., Ball, R. J., Plumb, R. S., Stumpf, C. L., Griffin, J. L., and Haselden, J. N. (2007). A gender-specific discriminator in Sprague-Dawley rat urine: the deployment of a metabolic profiling strategy for biomarker discovery and identification. Anal. Biochem. 362, 182-192.
94. Holmes, E., and Antti, H. (2002). Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Review 82 refs. Analyst. 127, 1549-1557.
95. Holmes, E., Foxall, P. J., Nicholson, J. K., Neild, G. H., Brown, S. M., Beddell, C. R., Sweatman, B. C., Rahr, E., Lindon, J. C., Spraul, M., et al. (1994). Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal. Biochem. 220, 284-296.
96. Holmes, E., Loo, R. L., Stamler, J., Bictash, M., Yap, I. K., Chan, Q., Ebbels, T., De Iorio, M., Brown, I. J., Veselkov, K. A., et al. (2008). Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400.
97. Holmes, E., and Shockcor, J. P. (2000). Accelerated toxicity screening using NMR and pattern recognition-based methods. Curr. Opin. Drug Discov. Dev. 3, 72-78.
98. Hu, Q., Noll, R. J., Li, H., Makarov, A., Hardman, M., and Cooks, R. G. (2005). The Orbitrap: a new mass spectrometer. J. Mass Spectrom. 40, 430-443.
99. Hummel, J., Selbig, J., Walther, D., and Kopka, J. (2007). The golm metabolome database: a database for GC-MS based metabolite profiling. In Topics in Current Genetics (J. Nielsen and M. C. Jewett, Eds.), Vol. 18, pp. 75-95. Springer-Verlag, Berlin, Germany.
100. Issaq, H. J., Nativ, O., Waybright, T., Luke, B., Veenstra, T. D., Issaq, E. J., Kravstov, A., and Mullerad, M. (2008). Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 179, 2422-2426.
101. Jellum, E., Stokke, O., and Eldjarn, L. (1971). Screening for metabolic disorders using gas-liquid chromatography, mass spectrometry, and computer technique. Scand. J. Clin. Lab. Invest. 27, 273-285.
102. Jones, A. R., Miller, M., Aebersold, R., Apweiler, R., Ball, C. A., Brazma, A., Degreef, J., Hardy, N., Hermjakob, H., Hubbard, S. J., et al. (2007). The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat. Biotechnol. 25, 1127-1133.
103. Kanani, H., Chrysanthopoulos, P. K., and Klapa, M. I. (2008). Standardizing GC-MS metabolomics. J. Chromatogr. 871, 191-201.
104. Katajamaa, M., and Oresic, M. (2007). Data processing for mass spectrometry-based metabolomics. J. Chromatogr. A 1158, 318-328.
105. Keisu, M., and Andersson, T. B. (2010). Drug-induced liver injury in humans: the case of ximelagatran. Handb. Exp. Pharmacol. 196, 407-418.
106. Keppler, D., Frohlich, J., Reutter, W., Wieland, O., and Decker, K. (1969). Changes in uridine nucleotides during liver perfusion with D-galactosamine. FEBS Lett. 4, 278-280.
107. Keppler, D., Lesch, R., Reutter, W., and Decker, K. (1968). Experimental hepatitis induced by D-galactosamine. Exp. Mol. Pathol. 9, 279-290.
108. Keun, H. C., Beckonert, O., Griffin, J. L., Richter, C., Moskau, D., Lindon, J. C., and Nicholson, J. K. (2002a). Cryogenic probe 13C NMR spectroscopy of urine for metabonomic studies. Anal. Chem. 74, 4588-4593.
109. Keun, H. C., Ebbels, T. M. D., Antti, H., Bollard, M. E., Beckonert, O., Schlotterbeck, G., Senn, H., Niederhauser, U., Holmes, E., Lindon, J. C., et al. (2002b). Analytical reproducibility in 1H NMR-based metabonomic urinalysis. Chem. Res. Toxicol. 15, 1380-1386.
110. Kilk, K., Mahlapuu, R., Soomets, U., and Langel, U. (2009). Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology 265, 87-95.
111. Kim, K., Aronov, P., Zakharkin, S. O., Anderson, D., Perroud, B., Thompson, I. M., and Weiss, R. H. (2009a). Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell. Proteomics 8, 558-570.
112. Kim, S., Sohn, I., and Lee, Y. S. (2005). Hepatic gene expression profiles are altered by genistein supplementation in mice with diet-induced obesity. J. Nutr. 135, 33-41.
113. Kim, S. H., Yang, S. O., Kim, H. S., Kim, Y., Park, T., and Choi, H. K. (2009b). 1H-nuclear magnetic resonance spectroscopy-based metabolic assessment in a rat model of obesity induced by a high-fat diet. Anal. Bioanal. Chem. 395, 1117-1124.
114. Kim, Y. S., Maruvada, P., and Milner, J. A. (2008). Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol. 4, 93-102.
115. Kimura, T., Noguchi, Y., Shikata, N., and Takahashi, M. (2009). Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr. Opin. Clin. Nutr. Metab. Care 12, 49-53.
116. Kind, T., Wohlgemuth, G., Lee, D. Y., Lu, Y., Palazoglu, M., Shahbaz, S., and Fiehn, O. (2009). FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal. Chem. 81, 10038-10048.
117. Kinross, J. M., von Roon, A. C., Holmes, E., Darzi, A., and Nicholson, J. K. (2008). The human gut microbiome: implications for future health care. Curr. Gastroenterol. Rep. 10, 396-403.
118. Klawitter, J., Haschke, M., Kahle, C., Dingmann, C., Leibfritz, D., and Christians, U. (2010a). Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br. J. Clin. Pharmacol. 70, 241-251.
119. Klawitter, J., Kushner, E., Jonscher, K., Bendrick-Peart, J., Leibfritz, D., Christians, U., and Schmitz, V. (2010b). Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J. Proteome Res. 9, 865-875.
120. Kleno, T. G., Kiehr, B., Baunsgaard, D., and Sidelmann, U. G. (2004). Combination of 'omics' data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers 9, 116-138.
121. Koal, T., and Deigner, H. P. (2010). Challenges in mass spectrometry based targeted metabolomics. Curr. Mol. Med. 10, 216-226.
122. Kochhar, S., Jacobs, D. M., Ramadan, Z., Berruex, F., Fuerholz, A., and Fay, L. B. (2006). Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal. Biochem. 352, 274-281.
123. Kombu, R. S., Zhang, G. F., Abbas, R., Mieyal, J. J., Anderson, V. E., Kelleher, J. K., Sanabria, J. R., and Brunengraber, H. (2009). Dynamics of glutathione and ophthalmate traced with 2H-enriched body water in rats and humans. Am. J. Physiol. Endocrinol. Metab. 297, E260-E269.
124. Kopka, J., Schauer, N., Krueger, S., Birkemeyer, C., Usadel, B., Bergmuller, E., Dormann, P., Weckwerth, W., Gibon, Y., Stitt, M., et al. (2005). GMD@CSB.DB: the Golm metabolome database. Bioinformatics 21, 1635-1638.
125. Kouba, E., Wallen, E. M., and Pruthi, R. S. (2007). Uroscopy by Hippocrates and Theophilus: prognosis versus diagnosis. J. Urol. 177, 50-52.
126. Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R., Newgard, C. B., et al. (2008). Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45-56.
127. Lane, A. N., Fan, T. W., and Higashi, R. M. (2008). Stable isotope-assisted metabolomics in cancer research. IUBMB Life 60, 124-129.
128. Lane, A. N., Fan, T. W., Higashi, R. M., Tan, J., Bousamra, M., and Miller, D. M. (2009). Prospects for clinical cancer metabolomics using stable isotope tracers. Exp. Mol. Pathol. 86, 165-173.
129. Lee, J. M., Gianchandani, E. P., and Papin, J. A. (2006). Flux balance analysis in the era of metabolomics. Brief. Bioinform. 7, 140-150.
130. Lee, W. M., Larrey, D., Olsson, R., Lewis, J. H., Keisu, M., Auclert, L., and Sheth, S. (2005). Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 28, 351-370.
131. Lehmann, R., Zhao, X., Weigert, C., Simon, P., Fehrenbach, E., Fritsche, J., Machann, J., Schick, F., Wang, J., Hoene, M., et al. (2010). Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation. PLoS ONE 5, e11519.
132. Lenz, E. M., Bright, J., Wilson, I. D., Hughes, A., Morrisson, J., Lindberg, H., and Lockton, A. (2004). Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal. 36, 841-849.
133. Lenz, E. M., and Wilson, I. D. (2007). Analytical strategies in metabonomics. J. Proteome Res. 6, 443-458.
134. Leo, G. C., and Darrow, A. L. (2009). NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magn. Reson. Chem. 47(Suppl. 1), S20-S25.
135. Li, H., Xie, Z., Lin, J., Song, H., Wang, Q., Wang, K., Su, M., Qiu, Y., Zhao, T., Song, K., et al. (2008). Transcriptomic and metabonomic profiling of obesity-prone and obesity-resistant rats under high fat diet. J. Proteome Res. 7, 4775-4783.
136. Li, L. O., Hu, Y. F., Wang, L., Mitchell, M., Berger, A., and Coleman, R. A. (2010a). Early hepatic insulin resistance in mice: a metabolomics analysis. Mol. Endocrinol. 24, 657-666.
137. Li, Y., Liu, S., Wang, C., Li, K., Shan, Y. J., Wang, X. J., and Sun, C. H. (2010b). Novel biomarkers of 3-chloro-1,2-propanediol exposure by ultra performance liquid chromatography/mass spectrometry based metabonomic analysis of rat urine. Chem. Res. Toxicol. 23, 1012-1017.
138. Limdi, N. A., and Veenstra, D. L. (2010). Expectations, validity, and reality in pharmacogenetics. J. Clin. Epidemiol. 63, 960-969.
139. Lin, H. M., Edmunds, S. I., Helsby, N. A., Ferguson, L. R., and Rowan, D. D. (2009). Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J. Proteome Res. 8, 2045-2057.
140. Lindon, J. C., Keun, H. C., Ebbels, T. M., Pearce, J. M., Holmes, E., and Nicholson, J. K. (2005). The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6, 691-699.
141. Lindon, J. C., and Nicholson, J. K. (2008). Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. Trends Anal. Chem. 27, 194-204.
142. Lindon, J. C., Nicholson, J. K., and Everett, J. R. (1999). NMR spectroscopy of biofluids. Annu. Rep. NMR Spectrosc. 38, 1-88.
143. Lindon, J. C., Nicholson, J. K., Holmes, E., Antti, H., Bollard, M. E., Keun, H., Beckonert, O., Ebbels, T. M., Reily, M. D., Robertson, D., et al. (2003). Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187, 137-146.
144. Lloyd, D. J., Wheeler, M. C., and Gekakis, N. (2010). A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice. Diabetes 59, 460-470.
145. Lu, W., Bennett, B. D., and Rabinowitz, J. D. (2008a). Analytical strategies for LC-MS-based targeted metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871, 236-242.
146. Lu, X., Zhao, X., Bai, C., Zhao, C., Lu, G., and Xu, G. (2008b). LC-MS-based metabonomics analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 866, 64-76.
147. Ludwig, C., and Viant, M. R. (2010). Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. Phytochem. Anal. 21, 22-32.
148. Ludwig, C., Ward, D. G., Martin, A., Viant, M. R., Ismail, T., Johnson, P. J., Wakelam, M. J. O., and GIunther, U. L. (2009). Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn. Reson. Chem. 47, S68-S73.
149. Madalinski, G., Godat, E., Alves, S., Lesage, D., Genin, E., Levi, P., Labarre, J., Tabet, J. C., Ezan, E., and Junot, C. (2008). Direct introduction of biological samples into a LTQ-orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis. Anal. Chem. 80, 3291-3303.
150. Madsen, R., Lundstedt, T., and Trygg, J. (2010). Chemometrics in metab-olomics-a review in human disease diagnosis. Anal. Chim. Acta 659, 23-33.
151. Maher, A. D., Lindon, J. C., and Nicholson, J. K. (2009). H NMR-based metabonomics for investigating diabetes. Future Med. Chem. 1, 737-747.
152. Makowski, L., Noland, R. C., Koves, T. R., Xing, W., Ilkayeva, O. R., Muehlbauer, M. J., Stevens, R. D., and Muoio, D. M. (2009). Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J. 23, 586-604.
153. Manna, S. K., Patterson, A. D., Yang, Q., Krausz, K. W., Li, H., Idle, J. R., Fornace, A. J., Jr.., and Gonzalez, F. J. (2010). Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. J. Proteome Res. 9, 4176-4188.
154. Martin, F. P., Dumas, M. E., Wang, Y., Legido-Quigley, C., Yap, I. K., Tang, H., Zirah, S., Murphy, G. M., Cloarec, O., Lindon, J. C., et al. (2007). A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 3, 112.
155. Martin, F. P., Rezzi, S., Philippe, D., Tornier, L., Messlik, A., Holzlwimmer, G., Baur, P., Quintanilla-Fend, L., Loh, G., Blaut, M., et al. (2009). Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J. Proteome Res. 8, 2376-2387.
156. Martin, F. P., Wang, Y., Sprenger, N., Yap, I. K., Lundstedt, T., Lek, P., Rezzi, S., Ramadan, Z., van Bladeren, P., Fay, L. B., et al. (2008). Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol. Syst. Biol. 4, 157.
157. Martin, G. E. (2005). Small-volume and high-sensitivity NMR probes. Annu. Rep. NMR Spectrosc. 56, 1-96.
158. Mayboroda, O. A., Neusüss, C., Pelzing, M., Zurek, G., Derks, R., Meulenbelt, I., Kloppenburg, M., Slagboom, E. P., and Deelder, A. M. (2007). Amino acid profiling in urine by capillary zone electrophoresis-mass spectrometry. J. Chromatogr. A 1159, 149-153.
159. Mayr, M., Metzler, B., Chung, Y. L., McGregor, E., Mayr, U., Troy, H., Hu, Y., Leitges, M., Pachinger, O., Griffiths, J. R., et al. (2004). Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. Am. J. Physiol. Heart Circ. Physiol. 287, H946-H956.
160. Mayr, M., Zampetaki, A., Sidibe, A., Mayr, U., Yin, X., De Souza, A. I., Chung, Y. L., Madhu, B., Quax, P. H., Hu, Y., et al. (2008). Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circ. Res. 102, 1046-1056.
161. McBurney, R. N., Hines, W. M., Von Tungeln, L. S., Schnackenberg, L. K., Beger, R. D., Moland, C. L., Han, T., Fuscoe, J. C., Chang, C. W., Chen, J. J., et al. (2009). The liver toxicity biomarker study: phase I design and preliminary results. Toxicol. Pathol. 37, 52-64.
162. Minami, Y., Kasukawa, T., Kakazu, Y., Iigo, M., Sugimoto, M., Ikeda, S., Yasui, A., van der Horst, G. T., Soga, T., and Ueda, H. R. (2009). Measurement of internal body time by blood metabolomics. Proc. Natl. Acad. Sci. U.S.A. 106, 9890-9895.
163. Monleon, D., Morales, J. M., Barrasa, A., Lopez, J. A., Vazquez, C., and Celda, B. (2009). Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 22, 342-348.
164. Monton, M. R. N., and Soga, T. (2007). Metabolome analysis by capillary electrophoresis-mass spectrometry. J. Chromatogr. A 1168, 237-246.
165. Mortishire-Smith, R. J., Skiles, G. L., Lawrence, J. W., Spence, S., Nicholls, A. W., Johnson, B. A., and Nicholson, J. K. (2004). Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 17, 165-173.
166. Mukhopadhyay, R. (2007). Liquid NMR probes: oh so many choices. Anal. Chem. 79, 7959-7963.
167. Murdoch, T. B., Fu, H., MacFarlane, S., Sydora, B. C., Fedorak, R. N., and Slupsky, C. M. (2008). Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal. Chem. 80, 5524-5531.
168. Mutch, D. M., O'Maille, G., Wikoff, W. R., Wiedmer, T., Sims, P. J., and Siuzdak, G. (2007). Mobilization of pro-inflammatory lipids in obese Plscr3-deficient mice. Genome Biol. 8, R38.
169. Nagy, Z. P., Sakkas, D., and Behr, B. (2008). Symposium: innovative techniques in human embryo viability assessment. Non-invasive assessment of embryo viability by metabolomic profiling of culture media ('metab-olomics'). Reprod. Biomed. Online 17, 502-507.
170. Nam, H., Chung, B. C., Kim, Y., Lee, K., and Lee, D. (2009). Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 25, 3151-3157.
171. Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9, 311-326.
172. Nicholson, J. K. (2008). Use of metabolomics to study gut microorganisms. Annu. Rev. Nutr. Advance Access published on August 12, 2008; PMID: 19575596.
173. Nicholson, J. K., Holmes, E., and Wilson, I. D. (2005). Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3, 431-438.
174. Nicholson, J. K., Lindon, J. C., and Holmes, E. (1999). 'Metabonomics': understanding the metabolic responses of living systems to pathophysiolog-ical stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189.
175. Nicholson, J. K., and Wilson, I. D. (2003). Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. 2, 668-676.
176. Oakman, C., Tenori, L., Biganzoli, L., Santarpia, L., Cappadona, S., Luchinat, C., and Di Leo, A. (2010). Uncovering the metabolomic fingerprint of breast cancer. Int. J. Biochem. Cell Biol. Advance Access published on May 10, 2010; doi:10.1016/j.biocel.2010.05.001.
177. Odunsi, K., Wollman, R. M., Ambrosone, C. B., Hutson, A., McCann, S. E., Tammela, J., Geisler, J. P., Miller, G., Sellers, T., Cliby, W., et al. (2005). Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int. J. Cancer 113, 782-788.
178. Olsson, S. B. (2003). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698.
179. Oresic, M. (2009). Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr. Metab. Cardiovasc. Dis. 19, 816-824.
180. Oresic, M. (2010). Systems biology strategy to study lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 1801, 235-239.
181. Osl, M., Dreiseitl, S., Pfeifer, B., Weinberger, K., Klocker, H., Bartsch, G., Schafer, G., Tilg, B., Graber, A., and Baumgartner, C. (2008). A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 24, 2908-2914.
182. Pan, Z., Gu, H., Talaty, N., Chen, H., Shanaiah, N., Hainline, B. E., Cooks, R. G., and Raftery, D. (2007). Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem. 387, 539-549.
183. Pan, Z., and Raftery, D. (2007). Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem.y 387, 525-527.
184. Parida, S. K., and Kaufmann, S. H. (2010). The quest for biomarkers in tuberculosis. Drug Discov. Today 15, 148-157.
185. Parsons, H. M., Ludwig, C., and Viant, M. R. (2009). Line-shape analysis of J-resolved NMR spectra: application tometabolomics and quantification of intensity errors from signal processing and high signal congestion. Magn. Reson, Chem. 47, S86-S95.
186. Pasikanti, K. K., Ho, P. C., and Chan, E. C. Y. (2008a). Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites. Rapid Commun. Mass Spectrom. 22, 2984-2992.
187. Pasikanti, K. K., Ho, P. C., and Chan, E. C. Y. (2008b). Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871, 202-211.
188. Pauling, L., Robinson, A. B., Teranishi, R., and Cary, P. (1971). Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad. Sci. U.S.A. 68, 2374-2376.
189. Payne, H., and Cornford, P. (2010). Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol. Oncol. Advance Access published on November 3, 2010; doi: 10.1016/j.urolonc.2009.11.003.
190. Pears, M. R., Cooper, J. D., Mitchison, H. M., Mortishire-Smith, R. J., Pearce, D. A., and Griffin, J. L. (2005). High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of batten disease. J. Biol. Chem. 280, 42508-42514.
191. Pendyala, G., Want, E. J., Webb, W., Siuzdak, G., and Fox, H. S. (2007). Biomarkers for neuroAIDS: the widening scope of metabolomics. J. Neuroimmune Pharmacol. 2, 72-80.
192. Phapale, P. B., Kim, S. D., Lee, H. W., Lim, M., Kale, D. D., Kim, Y. L., Cho, J. H., Hwang, D., and Yoon, Y. R. (2010). An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacoki-netics of tacrolimus. Clin. Pharmacol. Ther. 87, 426-436.
193. Phillips, M., Altorki, N., Austin, J. H., Cameron, R. B., Cataneo, R. N., Greenberg, J., Kloss, R., Maxfield, R. A., Munawar, M. I., Pass, H. I., et al. (2007). Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 3, 95-109.
194. Phillips, M., Cataneo, R. N., Ditkoff, B. A., Fisher, P., Greenberg, J., Gunawardena, R., Kwon, C. S., Tietje, O., and Wong, C. (2006). Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res. Treat. 99, 19-21.
195. Plumb, R., Granger, J., Stumpf, C., Wilson, I. D., Evans, J. A., and Lenz, E. M. (2003). Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences. Analyst. 128, 819-823.
196. Poli, D., Carbognani, P., Corradi, M., Goldoni, M., Acampa, O., Balbi, B., Bianchi, L., Rusca, M., and Mutti, A. (2005). Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir. Res. 6, 71.
197. Quinones, M. P., and Kaddurah-Daouk, R. (2009). Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35, 165-176.
198. Rabinowitz, J. D. (2007). Cellular metabolomics of Escherchia coli. Expert Rev. Proteomics 4, 187-198.
199. Reily, M. D., and Lindon, J. C. (2005). NMR spectroscopy: principles and instrumentation. In Metabonomics in Safety Assessment (J. C. L. D. G. Robertson, E. Holmes, and J. K. Nicholson, Eds.), pp. 75-104. Taylor & Francis, New York, NY.
200. Reily, M. D., P., S., and Hnatyshyn, S. (2011). LC-MS in endogenous metabolite profiling and small molecule biomarker discovery. In Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications (M. S. Lee and M. Zhu, Eds.), pp. 673-710. John Wiley and Sons, Hoboken, NJ.
201. Revelli, A., Delle Piane, L., Casano, S., Molinari, E., Massobrio, M., and Rinaudo, P. (2009). Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. Reprod. Biol. Endocrinol. 7, 40.
202. Robertson, D. G. (2005). Metabonomics in toxicology: a review. Toxicol. Sci. 85, 809-822.
203. Robertson, D. G. (2008). The muddle of models: what you don't know can hurt you. Chem. Res. Toxicol. 21, 1917-1922.
204. Robertson, D. G., Reily, M. D., and Baker, J. D. (2005). Metabonomics in preclinical drug development. Expert Opin. Drug Metab. Toxicol. 1, 363-376.
205. Robertson, D. G., Reily, M. D., and Baker, J. D. (2007). Metabonomics in pharmaceutical discovery and development. J. Proteome Res. 6, 526-539.
206. Robertson, D. G., Reily, M. D., Lindon, J. C., Holmes, E., and Nicholson, J. K. (2002). Metabonomic technology as a tool for rapid throughput in vivo toxicity screening. In Comprehensive Toxicology (J. P. Vanden Heuvel, G. J. Perdew, W. B. Mattes, and W. F. Greenlee, Eds.), Vol. 14, pp. 583-610. Elsevier Science BV, Amsterdam, The Netherlands.
207. Robertson, D. G., Reily, M. D., Sigler, R. E., Wells, D. F., Paterson, D. A., and Braden, T. K. (2000). Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 57, 326-337.
208. Robosky, L. C., Reily, M. D., and Avizonis, D. (2007). Improving NMR sensitivity by use of salt-tolerant cryogenically cooled probes. Anal. Bioanal. Chem. 387, 529-532.
209. Robosky, L. C., Robertson, D. G., Baker, J. D., Rane, S., and Reily, M. D. (2002). In vivo toxicity screening programs using metabonomics. Review 24 refs. Comb. Chem. High Throughput Screen. 5, 651-662.
210. Robosky, L. C., Wells, D. F., Egnash, L. A., Manning, M. L., Reily, M. D., and Robertson, D. G. (2005). Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 87, 277-284.
211. Robosky, L. C., Wells, D. F., Egnash, L. A., Manning, M. L., Reily, M. D., and Robertson, D. G. (2006). Communication regarding metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 91, 309.
212. Rohde, C. M., Wells, D. F., Robosky, L. C., Manning, M. L., Clifford, C. B., Reily, M. D., and Robertson, D. G. (2007). Metabonomic evaluation of Schaedler altered microflora rats. Chem. Res. Toxicol. 20, 1388-1392.
213. Roy, S. M., Anderle, M., Lin, H., and Becker, C. H. (2004). Differential expresion profiling of serum proteins and metabolites for biomarker discovery. Int. J. Mass Spectrom. 15, 580-584.
214. Rubtsov, D. V., Waterman, C., Currie, R. A., Waterfield, C., Salazar, J. D., Wright, J., and Griffin, J. L. (2010). Application of a Bayesian deconvolution approach for high-resolution (1)H NMR spectra to assessing the metabolic effects of acute phenobarbital exposure in liver tissue. Anal. Chem. 82, 4479-4485.
215. Rudolph, M. C., McManaman, J. L., Phang, T., Russell, T., Kominsky, D. J., Serkova, N. J., Stein, T., Anderson, S. M., and Neville, M. C. (2007). Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine. Physiol. Genomics 28, 323-336.
216. Rull, A., Vinaixa, M., Angel Rodriguez, M., Beltran, R., Brezmes, J., Canellas, N., Correig, X., and Joven, J. (2009). Metabolic phenotyping of genetically modified mice: an NMR metabonomic approach. Biochimie 91, 1053-1057.
217. Salek, R. M., Xia, J., Innes, A., Sweatman, B. C., Adalbert, R., Randle, S., McGowan, E., Emson, P. C., and Griffin, J. L. (2010). A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. Int. 56, 937-947.
218. Sana, T. R., Roark, J. C., Li, X., Waddell, K., and Fischer, S. M. (2008). Molecular formula and METLIN Personal Metabolite Database matching applied to the identification of compounds generated by LC/TOF-MS. J. Biomol. Tech. 19, 258-266.
219. Sands, C. J., Coen, M., Maher, A. D., Ebbels, T. M. D., Holmes, E., Lindon, J. C., and Nicholson, J. K. (2009). Statistical total correlation spectroscopy editing of 1H NMR spectra of biofluids: application to drug metabolite profile identification and enhanced information recovery. Anal. Chem. 81, 6458-6466.
220. Scalbert, A., Brennan, L., Fiehn, O., Hankemeier, T., Kristal, B. S., van Ommen, B., Pujos-Guillot, E., Verheij, E., Wishart, D., and Wopereis, S. (2009). Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics 5, 435-458.
221. Sciarra, A., Panebianco, V., Ciccariello, M., Salciccia, S., Cattarino, S., Lisi, D., Gentilucci, A., Alfarone, A., Bernardo, S., Passariello, R., et al. (2010). Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin. Cancer Res. 16, 1875-1883.
222. Seeger, K. (2009). Metabolic changes in autoimmune diseases. Curr. Drug Discov. Technol. 6, 256-261.
223. Seli, E., Botros, L., Sakkas, D., and Burns, D. H. (2008). Noninvasive metabolomic profiling of embryo culture media using proton nuclear magnetic resonance correlates with reproductive potential of embryos in women undergoing in vitro fertilization. Fertil. Steril. 90, 2183-2189.
224. Senior, J. R. (2009). Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin. Pharmacol. Ther. 85, 331-334.
225. Serkova, N. J., Spratlin, J. L., and Eckhardt, S. G. (2007). NMR-based metabolomics: translational application and treatment of cancer. Curr. Opin. Mol. Ther. 9, 572-585.
226. Shaykhutdinov, R. A., MacInnis, G. D., Dowlatabadi, R., Weljie, A. M., and Vogel, H. J. (2009). Quantitative analysis of metabolite concentrations in human urine samples using 13C{1H} NMR spectroscopy. Metabolomics 5, 1-11.
227. Shimizu, Y. I., Sunaga, E., Aoyagi, S., Kanazawa, K., Takahashi, S., Takahashi, Y., and Nemoto, T. (2009). Developmental delineation of metabolic-patterns of neonatal mice by using NMR-metabolic profiling on highly-diluted urine. J. Toxicol. Sci. 34, 343-347.
228. Sieber, M., Hoffmann, D., Adler, M., Vaidya, V. S., Clement, M., Bonventre, J. V., Zidek, N., Rached, E., Amberg, A., Callanan, J. J., et al. (2009). Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci. 109, 336-349.
229. Sitter, B., Bathen, T. F., Singstad, T. E., Fjosne, H. E., Lundgren, S., Halgunset, J., and Gribbestad, I. S. (2010). Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 23, 424-431.
230. Sitter, B., Lundgren, S., Bathen, T. F., Halgunset, J., Fjosne, H. E., and Gribbestad, I. S. (2006). Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 19, 30-40.
231. Slupsky, C. M. (2010). NMR-based analysis of metabolites in urine provides rapid diagnosis and etiology of pneumonia. Biomark. Med. 4, 195-197.
232. Slupsky, C. M., Rankin, K. N., Wagner, J., Fu, H., Chang, D., Weljie, A. M., Saude, E. J., Lix, B., Adamko, D. J., Shah, S., et al. (2007). Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal. Chem. 79, 6995-7004.
233. Smith, C. A., O'Maille, G., Want, E. J., Qin, C., Trauger, S. A., Brandon, T. R., Custodio, D. E., Abagyan, R., and Siuzdak, G. (2005). METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27, 747-751.
234. Soga, T., Baran, R., Suematsu, M., Ueno, Y., Ikeda, S., Sakurakawa, T., Kakazu, Y., Ishikawa, T., Robert, M., Nishioka, T., et al. (2006). Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 281, 16768-16776.
235. Spratlin, J. L., Serkova, N. J., and Eckhardt, S. G. (2009). Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440.
236. Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
237. Srivastava, A., Maggs, J. L., Antoine, D. J., Williams, D. P., Smith, D. A., and Park, B. K. (2010). Role of reactive metabolites in drug-induced hepatotoxicity. Handb. Exp. Pharmacol. 196, 165-194.
238. Staab, J. M., O'Connell, T. M., and Gomez, S. M. Enhancing metabolomic data analysis with Progressive Consensus Alignment of NMR Spectra (PCANS). BMC Bioinformatics 11, article number 123.
239. Stachlewitz, R. F., Seabra, V., Bradford, B., Bradham, C. A., Rusyn, I., Germolec, D., and Thurman, R. G. (1999). Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells. Hepatology 29, 737-745.
240. Stella, C., Beckwith-Hall, B., Cloarec, O., Holmes, E., Lindon, J. C., Powell, J., van der Ouderaa, F., Bingham, S., Cross, A. J., and Nicholson, J. K. (2006). Susceptibility of human metabolic phenotypes to dietary modulation. J. Proteome Res. 5, 2780-2788.
241. Stoyanova, R., Nicholls, A. W., Nicholson, J. K., Lindon, J. C., and Brown, T. R. (2004). Automatic alignment of individual peaks in large high-resolution spectral data sets. J. Magn. Reson. 170, 329-335.
242. Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T., and Tomita, M. (2010). Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6, 78-95.
243. Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., Fan, T. W. M., Fiehn, O., Goodacre, R., Griffin, J. L., et al. (2007). Proposed minimum reporting standards for chemical analysis. Metabolomics 3, 211-221.
244. Tautenhahn, R., Bottcher, C., and Neumann, S. (2008). Highly sensitive feature detection for high resolution LC/MS. BMC Bioinformatics 9.
245. Teichert, F., Verschoyle, R. D., Greaves, P., Edwards, R. E., Teahan, O., Jones, D. J., Wilson, I. D., Farmer, P. B., Steward, W. P., Gant, T. W., et al. (2008). Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. Prostate 68, 1035-1047.
246. Tiziani, S., Lopes, V., and Gunther, U. L. (2009). Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 11, 269-276; 4p following 269.
247. Toye, A. A., Dumas, M. E., Blancher, C., Rothwell, A. R., Fearnside, J. F., Wilder, S. P., Bihoreau, M. T., Cloarec, O., Azzouzi, I., Young, S., et al. (2007). Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice. Diabetologia 50, 1867-1879.
248. Tsang, T. M., Woodman, B., McLoughlin, G. A., Griffin, J. L., Tabrizi, S. J., Bates, G. P., and Holmes, E. (2006). Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J. Proteome Res. 5, 483-492.
249. Tweeddale, H., Notley-Mcrobb, L., and Ferenci, T. (1998). Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ('metabolome') analysis. J. Bacteriol. 180, 5109-5116.
250. Underwood, B. R., Broadhurst, D., Dunn, W. B., Ellis, D. I., Michell, A. W., Vacher, C., Mosedale, D. E., Kell, D. B., Barker, R. A., Grainger, D. J., et al. (2006). Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129, 877-886.
251. Urayama, S., Zou, W., Brooks, K., and Tolstikov, V. (2010). Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 24, 613-620.
252. Van, Q. N., Issaq, H. J., Jiang, Q., Li, Q., Muschik, G. M., Waybright, T. J., Lou, H., Dean, M., Uitto, J., and Veenstra, T. D. (2008). Comparison of 1D and 2D NMR spectroscopy for metabolic profiling. J. Proteome Res. 7, 630-639.
253. van Vliet, E., Morath, S., Eskes, C., Linge, J., Rappsilber, J., Honegger, P., Hartung, T., and Coecke, S. (2008). A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 29, 1-12.
254. Vasan, R. S. (2006). Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113, 2335-2362.
255. Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G., and Starzl, T. (1995). Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29, 404-430.
256. Villas-Boas, S. G., Mas, S., Akesson, M., Smedsgaard, J., and Nielsen, J. (2005). Mass spectrometry in metabolome analysis. Mass Spectrom. Rev. 24, 613-646.
257. Vinaixa, M., Rodriguez, M. A., Rull, A., Beltran, R., Blade, C., Brezmes, J., Canellas, N., Joven, J., and Correig, X. (2010). Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J. Proteome Res. 9, 2527-2538.
258. Vinayavekhin, N., Homan, E. A., and Saghatelian, A. (2010). Exploring disease through metabolomics. ACS Chem. Biol. 5, 91-103.
259. Vinayavekhin, N., and Saghatelian, A. Untargeted metabolomics. Curr. Protoc. Mol. Biol. 90, 30.1.1-30.1.24.
260. Vulimiri, S. V., Misra, M., Hamm, J. T., Mitchell, M., and Berger, A. (2009). Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chem. Res. Toxicol. 22, 492-503.
261. Walko, C. M., and McLeod, H. (2009). Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat. Clin. Pract. Oncol. 6, 153-162.
262. Wang, D., and Bodovitz, S. (2010). Single cell analysis: the new frontier in 'omics.' Trends Biotechnol. 28, 281-290.
263. Wang, J., Yu, L. F., Shen, P., and Wang, S. F. (2009). Analysis of serum metabonome of patients with breast cancer by gas chromatography-mass spectrometry. Zhejiang Da Xue Xue Bao Yi Xue Ban 38, 478-484.
264. Want, E. J., Coen, M., Masson, P., Keun, H. C., Pearce, J. T., Reily, M. D., Robertson, D. G., Rohde, C. M., Holmes, E., Lindon, J. C., et al. (2010a). Ultra performance liquid chromatography-mass spectrometry profiling of bile acid metabolites in biofluids: application to experimental toxicology studies. Anal. Chem. 82, 5282-5289.
265. Want, E. J., Nordström, A., Morita, H., and Siuzdak, G. (2007). From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J. Proteome Res. 6, 459-468.
266. Want, E. J., Wilson, I. D., Gika, H., Theodoridis, G., Plumb, R. S., Shockcor, J., Holmes, E., and Nicholson, J. K. (2010b). Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5, 1005-1018.
267. Warrack, B. M., Hnatyshyn, S., Ott, K. H., Reily, M. D., Sanders, M., Zhang, H., and Drexler, D. M. (2009). Normalization strategies for metabonomic analysis of urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 547-552.
268. Waterfield, C. J., Jairath, M., Asker, D. S., and Timbrell, J. A. (1995). The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage. Euro. J. Pharmacol. 293, 141-149.
269. Waters, N. J., Waterfield, C. J., Farrant, R. D., Holmes, E., and Nicholson, J. K. (2006). Integrated metabonomic analysis of bromobenzene-induced hepato-toxicity: novel induction of 5-oxoprolinosis. J. Proteome Res. 5, 1448-1459.
270. Watkins, P. B. (2009). Biomarkers for the diagnosis and management of drug-induced liver injury. Semin. Liver Dis. 29, 393-399.
271. Watkins, P. B., Kaplowitz, N., Slattery, J. T., Colonese, C. R., Colucci, S. V., Stewart, P. W., and Harris, S. C. (2006). Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296, 87-93.
272. Watkins, P. B., Seligman, P. J., Pears, J. S., Avigan, M. I., and Senior, J. R. (2008). Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48, 1680-1689.
273. Wen, H., Yoo, S. S., Kang, J., Kim, H. G., Park, J. S., Jeong, S., Lee, J. I., Kwon, H. N., Kang, S., Lee, D. H., et al. (2010). A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J. Hepatol. 52, 228-233.
274. West, P. R., Weir, A. M., Smith, A. M., Donley, E. L., and Cezar, G. G. (2010). Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 247, 18-27.
275. Wetmore, D. R., Joseloff, E., Pilewski, J., Lee, D. P., Lawton, K. A., Mitchell, M. W., Milburn, M. V., Ryals, J. A., and Guo, L. (2010). Metabolomic profiling revealed biochemical pathways and biomarkers associated with pathogensis in cystic fibrosis cells. J. Biol. Chem. 285, 30516-30522.
276. Wheatley, D. N. (2005). Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin. Cancer Biol. 15, 247-253.
277. Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., and Siuzdak, G. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U.S. A. 106, 3698-3703.
278. Wikoff, W. R., Gangoiti, J. A., Barshop, B. A., and Siuzdak, G. (2007). Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin. Chem. 53, 2169-2176.
279. Williams, R., Lenz, E., Lowden, J., Rantalainen, M., and Wilson, I. (2005). The metabonomics of aging and development in the rat: an investigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using 1H NMR and HPLC-TOF MS. Mol. Biosyst. 1, 166-175.
280. Wilson, I. D., Nicholson, J. K., Castro-Perez, J., Granger, J. H., Johnson, K. A., Smith, B. W., and Plumb, R. S. (2005). High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 4, 591-598.
281. Winnike, J. H., Li, Z., Wright, F. A., Macdonald, J., O'Connell, T. M., and Watkins, P. B. (2010). Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88, 45-51.
282. Wishart, D. S. (2008). Quantitative metabolomics using NMR. Trends Analyt. Chem. 27, 228-237.
283. Wishart, D. S., Knox, C., Guo, A. C., Eisner, R., Young, N., Gautam, B., Hau, D. D., Psychogios, N., Dong, E., Bouatra, S., et al. (2009). HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 37 (suppl. 1), D603-D610.
284. Wolf, C., and Quinn, P. J. (2008). Lipidomics: practical aspects and applications. Prog. Lipid Res. 47, 15-36.
285. Wong, H., Lehman-McKeeman, L. D., Grubb, M. F., Grossman, S. J., Bhaskaran, V. M., Solon, E. G., Shen, H. S., Gerson, R. J., Car, B. D., Zhao, B., et al. (2005). Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 84, 232-242.
286. Xia, J., Bjorndahl, T. C., Tang, P., and Wishart, D. S. (2008). MetaboMiner-semi-automated identification of metabolites from 2D NMR spectra of complex biofluids. BMC Bioinformatics 9.
287. Yan, S. K., Wei, B. J., Lin, Z. Y., Yang, Y., Zhou, Z. T., and Zhang, W. D. (2008). A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol. 44, 477-483.
288. Yang, L., Xiong, A., He, Y., Wang, Z., Wang, C., Wang, Z., Li, W., Yang, L., and Hu, Z. (2008). Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem. Res. Toxicol. 21, 2280-2288.
289. Yi, L. Z., He, J., Liang, Y. Z., Yuan, D. L., and Chau, F. T. (2006). Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA. FEBS Lett. 580, 6837-6845.
290. Young, S. P., and Wallace, G. R. (2009). Metabolomic analysis of human disease and its application to the eye. J. Ocul. Biol. Dis. Infor. 2, 235-242.
291. Young, V. R., Havenberg, L. N., Bilmazes, C., and Munro, H. N. (1973). Potential use of 3-methylhistidine excretion as an index of progressive reduction in muscle protein catabolism during starvation. Metab. Clin. Exp. 23, 1429-1436.
292. Zhai, G., Wang-Sattler, R., Hart, D. J., Arden, N. K., Hakim, A. J., Illig, T., and Spector, T. D. (2010). Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann. Rheum. Dis. 69, 1227-1231.
293. Zhen, Y., Krausz, K. W., Chen, C., Idle, J. R., and Gonzalez, F. J. (2007). Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol. Endocrinol. 21, 2136-2151.